Get the Stockscreener App
23.75
4.29%
-1.065
Edgewise Therapeutics Inc stock is traded at $23.75, with a volume of 1.00M.
It is down -4.29% in the last 24 hours and up +3.35% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$24.82
Open:
$25.08
24h Volume:
1.00M
Relative Volume:
0.78
Market Cap:
$2.51B
Revenue:
-
Net Income/Loss:
$-150.70M
P/E Ratio:
-15.32
EPS:
-1.55
Net Cash Flow:
$-125.67M
1W Performance:
-9.87%
1M Performance:
+3.35%
6M Performance:
+82.55%
1Y Performance:
-12.13%
1-Day Range:
$23.66
$25.08
1-Week Range:
$23.66
$26.54
52-Week Range:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
23.75 | 2.63B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits - The Globe and Mail
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
What drives Edgewise Therapeutics Inc stock priceHigh Dividend Yield Stocks & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2%Here's Why - MarketBeat
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ts2.tech
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - BioSpace
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout - Stocktwits
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance
Edgewise Stock (+26%): Phase 2 HCM Safety Data Forces a Re-Rate - Trefis
Why Edgewise Therapeutics Stock Rocked the Market Today - Finviz
Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating - TipRanks
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics rises on positive safety data from heart disease drug trial - TradingView — Track All Markets
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Why Is Edgewise Therapeutics Stock Soaring Wednesday? - Benzinga
Edgewise reports positive interim safety data for HCM drug EDG-7500 - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update By Investing.com - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update - Investing.com
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRU - GuruFocus
Edgewise Completed Phase 2 CIRRUS-HCM Parts B And C, Reports Favorable Interim Safety From Part D - Nasdaq
Edgewise Therapeutics Completes Parts B and C of Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Edgewise reports positive interim safety data for HCM drug EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc on track to deliver full 12-week part D readout in 2Q 2026 and phase 3 start in 4Q 2026 - marketscreener.com
Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026 - TradingView — Track All Markets
Edgewise Therapeutics Announces Completion of the EDG-7500 Cirrus-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - marketscreener.com
Insider Trends: Is Edgewise Therapeutics Inc stock vulnerable to regulatory risksQuarterly Profit Summary & Expert Curated Trade Setups - moha.gov.vn
Can Edgewise Therapeutics Inc. stock double in next 5 yearsLow Beta Stocks & Use Smart Algorithms to Pick Better Stocks - bollywoodhelpline.com
Edgewise Therapeutics (EWTX) Stock News Today: What’s Driving the Volatility, Analyst Forecasts, and Key Catalysts (Dec. 22, 2025) - ts2.tech
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):